Wall Street brokerages forecast that Horizon Pharma PLC (NASDAQ:HZNP) will announce $267.58 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Horizon Pharma’s earnings. The lowest sales estimate is $266.25 million and the highest is $268.91 million. Horizon Pharma reported sales of $310.35 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 13.8%. The company is expected to issue its next quarterly earnings report on Monday, February 26th.

According to Zacks, analysts expect that Horizon Pharma will report full-year sales of $267.58 million for the current fiscal year. For the next fiscal year, analysts expect that the business will post sales of $1.13 billion per share, with estimates ranging from $1.12 billion to $1.15 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that that provide coverage for Horizon Pharma.

Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.22 by $0.04. Horizon Pharma had a negative net margin of 45.28% and a positive return on equity of 20.22%. The firm had revenue of $271.60 million during the quarter, compared to analyst estimates of $259.74 million. During the same quarter in the prior year, the business posted $0.70 earnings per share. The company’s quarterly revenue was up 30.1% compared to the same quarter last year.

Several research firms recently issued reports on HZNP. Cantor Fitzgerald set a $17.00 price target on shares of Horizon Pharma and gave the stock a “buy” rating in a research report on Friday, December 1st. UBS set a $20.00 price objective on shares of Horizon Pharma and gave the stock a “buy” rating in a report on Thursday, November 30th. Jefferies Group raised their price objective on shares of Horizon Pharma from $16.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, November 7th. Stifel Nicolaus reaffirmed a “buy” rating and set a $20.00 price objective on shares of Horizon Pharma in a report on Sunday, October 22nd. Finally, ValuEngine raised shares of Horizon Pharma from a “hold” rating to a “buy” rating in a report on Monday, October 16th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $18.75.

Several institutional investors and hedge funds have recently added to or reduced their stakes in HZNP. Bank of Montreal Can grew its stake in shares of Horizon Pharma by 16.3% during the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 1,378 shares during the last quarter. US Bancorp DE boosted its stake in Horizon Pharma by 159.5% in the second quarter. US Bancorp DE now owns 83,165 shares of the biopharmaceutical company’s stock valued at $988,000 after acquiring an additional 51,115 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in Horizon Pharma by 82.8% in the second quarter. Russell Investments Group Ltd. now owns 153,668 shares of the biopharmaceutical company’s stock valued at $1,824,000 after acquiring an additional 69,626 shares during the last quarter. Rothschild Asset Management Inc. boosted its stake in Horizon Pharma by 21.9% in the second quarter. Rothschild Asset Management Inc. now owns 1,476,705 shares of the biopharmaceutical company’s stock valued at $17,528,000 after acquiring an additional 265,013 shares during the last quarter. Finally, Sei Investments Co. boosted its stake in Horizon Pharma by 14.1% in the second quarter. Sei Investments Co. now owns 232,168 shares of the biopharmaceutical company’s stock valued at $2,756,000 after acquiring an additional 28,700 shares during the last quarter. 86.59% of the stock is currently owned by institutional investors and hedge funds.

Horizon Pharma (NASDAQ HZNP) traded up $0.04 during trading hours on Friday, reaching $14.48. 1,272,899 shares of the company traded hands, compared to its average volume of 3,433,109. Horizon Pharma has a 52-week low of $9.45 and a 52-week high of $20.03. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.64 and a quick ratio of 1.52. The firm has a market capitalization of $2,304.23, a price-to-earnings ratio of 10.19, a PEG ratio of 1.19 and a beta of 1.31.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Expect Horizon Pharma PLC (HZNP) Will Announce Quarterly Sales of $267.58 Million” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/06/zacks-analysts-expect-horizon-pharma-plc-hznp-will-announce-quarterly-sales-of-267-58-million.html.

About Horizon Pharma

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Get a free copy of the Zacks research report on Horizon Pharma (HZNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Horizon Pharma (NASDAQ:HZNP)

Receive News & Stock Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related stocks with our FREE daily email newsletter.